Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 212

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 212
---
, “poison pill” or similar arrangement that is, or at the Effective Time will be, 
 applicable to the Merger Agreement, the Transactions or the other transactions contemplated thereby; |

| • |     | engage in any transaction with, or enter into any agreement, arrangement or understanding with, any affiliate of                                   
 Enfusion or other person covered by Item 404 of Regulation S-K promulgated by the SEC that would be required to be disclosed pursuant to Item 404; |

| • |     | (1) amend the terms of the TRA or the TRA Amendment, or (2) make any payment to any TRA Party under the TRA, 
 in each case of clauses (1) and (2), except as set forth in the TRA Amendment; or                            |

| • |     | authorize, commit or agree to take any of the foregoing actions. |

No Solicitation of Other Offers by Enfusion For purposes of this Proxy Statement/Prospectus and the Merger Agreement: “ Acceptable Confidentiality Agreement” means a confidentiality agreement containing confidentiality and use terms not materially less restrictive in the aggregate to the counterparty thereto than the confidentiality and use terms of the Confidentiality Agreement (as defined in the Merger Agreement) (such confidentiality agreement need not contain any “standstill” or similar provisions or otherwise prohibit the making, or amendment, of any Acquisition Proposal); provided, however, that such confidentiality agreement will contain provisions that permit Enfusion to comply with the provisions of Article VIof the Merger Agreement. 132

“” means any inquiry, offer or proposal from any third
party relating to any transaction or series of related transactions involving (i) any acquisition or purchase by any third party, directly or indirectly, of 20% or more of the voting power of the capital stock of Enfusion and its subsidiaries
(including securities convertible into or exercisable or exchangeable for equity or voting securities), or any tender offer, exchange offer, share issuance or other similar transaction that, if consummated, would result in any third party
beneficially owning 20% or more of the voting power of the capital stock of Enfusion and its subsidiaries (including securities convertible into or exercisable or exchangeable for equity or voting securities), (ii) any merger, amalgamation,
consolidation, share exchange, business combination, joint venture or other similar transaction involving Enfusion or any of its subsidiaries, pursuant to which a third party would (x) acquire, directly or indirectly